DelMar to acquire Adgero Biopharmaceuticals in all-equity transaction
By Nikita Chaurasia  Date: 2020-06-11

DelMar to acquire Adgero Biopharmaceuticals in all-equity transaction

DelMar Pharmaceuticals, Inc., the American-based biopharmaceutical company focused on the development of novel cancer therapies, has reportedly inked agreement to acquire Adgero Biopharmaceuticals Holdings, Inc. in an all-equity transaction.

Sources cite that Adgero stockholders will get shares of DelMar common stock for shares of Adgero common stock. Following the completion of the deal, the stockholders of DelMar and Adgero will own 50.5 percent and 49.5 percent of the total voting power of the joint company respectively.

Expected to close in the Q3 2020, the deal is subject to stockholder approval of two companies and other closing conditions. Kintara Therapeutics, Inc. will be a new name for the combined company and expected to trade on NASDAQ under new symbol ‘KTRA’

The merger will create a diversified biopharmaceutical company with a vigorous product pipeline targeting unmet medical needs in oncology. The joint company will work on two late-stage, Phase 3-ready cancer treatments – VAL for GBM (glioblastoma multiforme) and REM-001 for CMB (cutaneous metastatic breast cancer). Moreover, the combined company will work on several last-state clinical research over the next 12-18 months.

For the record, Adgero is a biopharmaceutical company focused on developing its late-stage photodynamic therapy platform for treating serious cutaneous oncology indications. The joint company will bring together DelMar's DNA-targeting chemotherapeutic with proven anti-cancer activities with Adgero's last stage photodynamic therapy platform. 

Speaking on which, Saiid Zarrabian, Chief Executive Officer and President of DelMar said that this merger is the result of a widespread search for suitable oncology therapy and offers the combined company with a diversified last-stage oncology pipeline.

John Liatos, Chief Financial Officer and interim Chief Executive Officer of Adgero said that with this deal, the company is looking forward to developing a highly focused oncology company that can develop novel therapies to support patients and physicians where existing treatment options are limited.

Source Credit -https://www.delmarpharma.com/news-media/press-releases/detail/933/delmar-to-acquire-adgero-biopharmaceuticals-expand

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

WELL Health reveals plans to acquire Cycura’s services division
WELL Health reveals plans to acquire Cycura’s services division
By Nikita Chaurasia

  The acquisition would elevate WELL Health's cybersecurity program across the technology and healthcare sectors  WELL Health would build a strong portfolio of companies and products/services as part of its capital allocation initia...

Abry adds HealthEZ to its pool of healthcare service investments
Abry adds HealthEZ to its pool of healthcare service investments
By Nikita Chaurasia

Abry Partners, one of the most successful private equity investment firms in North America, has reportedly made it to the headlines for acquiring majority stake in a Minnesota-based third-party administrator of self-funded medical plans, HealthEZ. T...

Welltel acquires Kildare-based secure IT & cloud service provider Novi
Welltel acquires Kildare-based secure IT & cloud service provider Novi
By Nikita Chaurasia

Ireland-based end-to-end communication services provider, Welltel has recently announced the acquisition of Novi, a Kildare-based IT service firm. With the said acquisition the two companies would now be able to offer an integrated suite of secure co...

Canzon to explore German market by partnering with Lykos Verde
Canzon to explore German market by partnering with Lykos Verde
By Nikita Chaurasia

Canzon, an Israeli enterprise selling CBD-based products in Europe has reportedly entered a partnership worth NIS 6 million yearly with German distribution firm Lykos Verde. Sources close to the matter stated that as per the agreement, Lykos Verde w...

Société Générale purchases Shine to expand retail banking portfolio
Société Générale purchases Shine to expand retail banking portfolio
By Nikita Chaurasia

France-based multinational investment bank Société Générale S.A. has reportedly acquired Shine, a neobank for entrepreneurs, for an undisclosed sum. According to reliable sources, the acquisition will allow the financial s...